

NEWS RELEASE



September 17, 2021

VILTEPSO® (viltolarsen) injection Interim Long-Term Clinical Trial Data Scheduled for Presentation at the World Muscle Society 2021 Virtual Conference

Kyoto, Japan, September 17, 2021 – Nippon Shinyaku Co., LTD. (Nippon Shinyaku; Headquarters, Kyoto; President, Toru Nakai) announced today an electronic poster presentation on long-term efficacy and safety data (interim analysis at 109 weeks) from the open-label extension of a Phase 2 study of VILTEPSO® (viltolarsen) injection at the World Muscle Society 2021 Virtual Conference being held September 20–24 BST.

The electronic poster presentation will be given by Paula Clemens, MD from the University of Pittsburgh School of Medicine on Thursday, September 23rd from 16:30 to 18:30 BST. To access the presentation, you will need to register (charged) at the following site. For more information, please visit the World Muscle Society Virtual Conference website to view the full program: <https://www.wms2021.com/page/programme>.

About VILTEPSO

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. VILTEPSO received marketing authorization under the conditional early approval system in Japan in March 2020 and became commercially available in Japan in May of the same year. In the United States, it received accelerated approval from the US Food and Drug Administration (FDA) in August 2020 and has been marketed through NS Pharma, Inc.

About NS Pharma, Inc.

NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. For more information, please visit <https://www.nspharma.com>. NS Pharma is a registered trademark of the Nippon Shinyaku group of companies.

Contact

Corporate Communications Dept., Nippon Shinyaku Co., Ltd.

FAX: +81-75-321-9128